OUR STORY

Recent advances in DNA sequencing technologies have revolutionized our ability to discover and analyze specific genetic mutations. While sequencing is sensitive to single nucleotide polymorphisms (SNPs) and smaller genetic variants, current approaches are unable to resolve many of the disease-causing structural variants that may be present across an individual genome. With typical read lengths of 150 bases, short-read DNA sequencing platforms provide a very limited view of these structural changes, even with the application of super-computer-scale bioinformatics analysis. So-called ‘long-read’ technologies only analyze on average a few tens of thousands of bases, which is a tiny fraction of intact human chromosomes that range in size from 47 million to 250 million base pairs. Peer-reviewed publications* continue to cite the need for a technology capable of extracting and analyzing entire chromosomes to detect the full spectrum of structural variation and transform our understanding of the role it plays in cellular function, disease susceptibility and disease progression.

At the lab bench, simple tasks such as fragment sizing still require the use of cumbersome techniques such as gel electrophoresis. These methods can require large amounts of input sample and, for larger DNA fragments, require run times of a full day or longer. The ability to rapidly analyze DNA from a small number of cells would remove the need for cell culturing and allow the analysis of unculturable samples, such as needle biopsies and primary cells.

Genturi Co-founders, Prof. J. Michael Ramsey and Dr. Laurent Menard at the University of North Carolina at Chapel Hill, have dedicated the last decade to developing nanofluidic approaches capable of extracting and analyzing millions of DNA molecules, one-by-one. Genturi’s nanofluidic products will soon enable the rapid analysis of DNA molecules from 100 base pairs up to millions of base pairs, all in a single device.

Genturi is funded by a series A investment from Arch Venture Partners, Hatteras Venture Partners, Stillwater LLC, and Eleven Two Capital.

* Chiang et al. The impact of structural variation on human gene expression. Nature Genetics 49, 692-699 (2017).

* Nazarenko et al. Genomic structural variations for cardiovascular and metabolic comorbidity. Scientific Reports 7:41268 (2017).

* Collins et al. Defining the diverse spectrum of inversions, complex structural variation, and chromothripsis in the morbid human genome. Genome Biology 18:36 (2017).

* Chaisson et al. Genetic variation and the de novo assembly of human genomes. Nature Reviews Genetics 16, 627-640 (2015).

TECHNOLOGY AND PRODUCTS

Genturi’s nanofluidic products will have several key advantages over current methods:

  • High capacity and scalability – analyze thousands to millions of individual DNA molecules in as little as 5 minutes

  • Broad range of DNA sizes – detect and quantify DNA ranging in size from 100bp up to millions of base pairs

  • Minimal sample input requirements – perform routine analysis of small numbers of cells

  • Integrated micro and nanofluidics – minimize user operation with intuitive workflow

  • High volume single-use consumables – enable low overall cost per sample

Megabase Genomic DNA Extraction

Real-Time Mapping in Nanofluidic Networks

Single-Point Florescence Detection with Resolution Down to 100 Bases

LEADERSHIP TEAM

Genturi’s leadership team combines an established track record of breakthrough scientific innovation and entrepreneurial success. The team features diverse backgrounds from leading academic institutions and genomics technology companies.

J. Michael Ramsey, PhD
Scientific Founder
and Director
Read Bio

J. Michael Ramsey, PhD
Scientific Founder
and Director
Read Bio

Laurent D. Menard, PhD
Scientific Co-founder and
Director of Microfluidics Research
Read Bio

Laurent D. Menard, PhD
Scientific Co-founder and
Director of Microfluidics Research
Read Bio

Peter Honkanen
Chief Executive Officer
and Director
Read Bio

Peter Honkanen
Chief Executive Officer
and Director
Read Bio

Michael Dial, PhD
Director
Read Bio

Michael Dial, PhD
Director
Read Bio

Keith L. Crandell
Director
Read Bio

Keith L. Crandell
Director
Read Bio

Michael Albin, PhD
Director
Read Bio

Michael Albin, PhD
Director
Read Bio

CAREER OPPORTUNITIES

Genturi is currently actively recruiting top scientific and business talent. Our compensation packages include significant early stage equity, competitive salary, annual bonus, and health benefits. Contact us today to learn more at careers@genturi.com.

CONTACT US

Genturi is headquartered in Woburn, MA, a growing biotech and life sciences hub just north of Boston.

8 Cabot Road, Suite 3800

Woburn, MA 01801

Phone: 617-767-2362
Email: info@genturi.com

Genturi

Sign up today to join our growing community and receive email updates on our latest technology developments.

4 + 9 =

J. Michael Ramsey, PhD

Scientific Founder and Director

 

Dr. J. Michael Ramsey is the Scientific Founder and Director at Genturi. He also holds the Minnie N. Goldby Distinguished Professor of Chemistry Chair at the University of North Carolina - Chapel Hill.  In addition, he is a member of the faculty in the Departments of Biomedical Engineering and Applied Physical Sciences, and the Carolina Center for Genome Sciences. His present research interests include microfabricated chemical instrumentation, micro- and nanofluidics, single molecule DNA characterization, single cell assays, point-of-care clinical diagnostic devices, and highly miniaturized mass spectrometry.

Dr. Ramsey is a member of the National Academy of Engineering and a Fellow of the Optical Society of America, the American Chemical Society, and the American Institute for Medical and Biological Engineering. He is a recipient of a senior Alexander von Humboldt Award, the Frederick Capillary Electrophoresis Award, the A. J. P. Martin Gold Medal for Separation Science, the Marcel J.E. Golay Award in Capillary Chromatography, the Jacob Heskel Gabbay Award in Biotechnology and Medicine, the American Chemical Society Division of Analytical Chemistry Award in Chemical Instrumentation, the Pittsburgh Analytical Chemistry Award, the American Chemical Society Award in Chromatography, the CASSS Award for Outstanding Achievement in Separation Science, and the Ralph N. Adams Award in Bioanalytical Chemistry. Moreover, Dr. Ramsey is the sole scientific founder of Caliper Technologies (NASDAQ:CALP), renamed Caliper Life Sciences, and acquired by PerkinElmer in 2011. He is also the scientific founder of privately held 908 Devices Inc., a company developing revolutionary compact mass spectrometry and chemical separations-based products. Prof. Ramsey has published over 300 peer-reviewed papers (H-index = 61) and presented over 500 invited, plenary, or named lectures.  In addition, he has over 100 issued and 20 pending patents.

Laurent D. Menard, PhD

Scientific Co-founder and Director of Microfluidics Research

 

Dr. Laurent Menard is the Scientific Co-founder and Director of Microfluidics Research at Genturi Inc. He has a diverse background in the chemical sciences and has conducted research throughout his career with an underlying theme of innovation through nanotechnology. As a senior research scientist in the laboratory of Prof. J. Michael Ramsey at the University of North Carolina at Chapel Hill, he led a team of chemists and engineers developing nanofluidic platforms for high-throughput, high-resolution mapping of human genomes.

He is an expert in microfabrication and nanofabrication techniques, electron microscopy, surface chemistry, micro- and nanofluidics, and the characterization of biological macromolecules such as DNA using nanofluidic systems. Dr. Menard received a PhD in Analytical Chemistry from the University of Illinois at Urbana-Champaign in 2007, where he was supported through a NDSEG fellowship. He is an author on more than 25 peer reviewed journal articles and conference proceedings, an inventor on six pending and granted patents.

Peter Honkanen

Chief Executive Officer and Director

 

Peter Honkanen is the CEO and Director of Genturi Inc. He has served in leadership positions in the high tech and life science industries for the past 25 years. Prior to joining Genturi, Mr. Honkanen was the founding CEO of Aushon Biosystems, an ultra-sensitive, multiplexed immunoassay company acquired by Quanterix in January 2018. He also led the development and commercialization of numerous life science technologies at Affymetrix, Genetic Microsystems and General Scanning. He holds numerous patents covering the fabrication, processing and analysis of both genomic and proteomic assays.

Mr. Honkanen has an MS in Business Management from the Massachusetts Institute of Technology (MIT) Sloan School of Management and a BS in Electrical Engineering from Boston University. He is a former US Navy officer (Intelligence). He currently serves on the MIT Sloan Americas Executive Board.

Michael Dial, PhD

Director
Principal, Hatteras Venture Partners

 

Prior to joining Hatteras, Mike was a Vice President in Silicon Valley Bank’s Corporate Finance Scientific Founder and Director Scientific Co-founder and Group where he focused on emerging life science companies and venture capital funds. Prior Read Bio Director of Microfluidics Research to SVB, he held research scientist positions in the Department of Biochemistry at UNC-Chapel Hill, the Laboratory of Structural Biology at the National Institute of Environmental Health Sciences, and the UNC-Duke Michael Hooker Proteomics Center. He has performed research in the fields of cell cycle regulation, proteomics, and cancer therapy and holds a Ph.D. in Biochemistry and Biophysics from the University of North Carolina at Chapel Hill.

 

Mike is also the Manager of the Carolina Research Ventures Fund, a fund dedicated to UNC-Chapel Hill related start-ups. Mike serves on the boards of Genturi and Stride Therapeutics and is a board observer at Spyryx, Curoverse, and Lysosomal Therapeutics.

Keith L. Crandell

Director
Managing Director and Co-Founder, ARCH Venture Partners

 

Keith Crandell is a Managing Director and Co-Founder of ARCH Venture Partners, L.P., a global seed and early stage venture capital firm focused on innovations in the life and physical sciences. ARCH Venture partners is investing its ninth fund and manages $2.7 billion. Keith holds an M.B.A. from The University of Chicago (Booth), an M.S. in Chemistry from the University of Texas at Arlington, and a B.S. in Chemistry and Mathematics from St. Lawrence University.

Michael Albin, PhD

Director

 

Following a Ph.D. in chemistry at Pennsylvania State University and postdoctoral research in biochemistry at the California Institute of Technology, Michael worked at SYVA diagnostics followed by fifteen years at Applied Biosystems Inc rising to the role of VP of Science and Technology, and then VP of Strategic Technologies of the parent company Applera Corp, an S&P 500 company.

As VP of Science and Technology at Applied Biosystems Inc (now Life Technologies Inc.), Michael was responsible for R&D programs with a budget in excess of US$100 million and overseeing the development of the company’s product pipeline via internal development, investment and acquisition.

In recent years, Michael has worked as a private consultant focusing on technical and strategic assessments and the positioning of a wide range of companies in the life sciences, molecular diagnostics, and personalized medicine. In addition, he has been appointed to carry out due diligence for venture capital and other investment organizations worldwide.

J. Michael Ramsey, PhD

Scientific Founder and Director

 

Dr. J. Michael Ramsey is the Scientific Founder and Director at Genturi. He also holds the Minnie N. Goldby Distinguished Professor of Chemistry Chair at the University of North Carolina - Chapel Hill.  In addition, he is a member of the faculty in the Departments of Biomedical Engineering and Applied Physical Sciences, and the Carolina Center for Genome Sciences. His present research interests include microfabricated chemical instrumentation, micro- and nanofluidics, single molecule DNA characterization, single cell assays, point-of-care clinical diagnostic devices, and highly miniaturized mass spectrometry.

Dr. Ramsey is a member of the National Academy of Engineering and a Fellow of the Optical Society of America, the American Chemical Society, and the American Institute for Medical and Biological Engineering. He is a recipient of a senior Alexander von Humboldt Award, the Frederick Capillary Electrophoresis Award, the A. J. P. Martin Gold Medal for Separation Science, the Marcel J.E. Golay Award in Capillary Chromatography, the Jacob Heskel Gabbay Award in Biotechnology and Medicine, the American Chemical Society Division of Analytical Chemistry Award in Chemical Instrumentation, the Pittsburgh Analytical Chemistry Award, the American Chemical Society Award in Chromatography, the CASSS Award for Outstanding Achievement in Separation Science, and the Ralph N. Adams Award in Bioanalytical Chemistry. Moreover, Dr. Ramsey is the sole scientific founder of Caliper Technologies (NASDAQ:CALP), renamed Caliper Life Sciences, and acquired by PerkinElmer in 2011. He is also the scientific founder of privately held 908 Devices Inc., a company developing revolutionary compact mass spectrometry and chemical separations-based products. Prof. Ramsey has published over 300 peer-reviewed papers (H-index = 61) and presented over 500 invited, plenary, or named lectures.  In addition, he has over 100 issued and 20 pending patents.

Laurent D. Menard, PhD

Scientific Co-founder and Director of Microfluidics Research

 

Dr. Laurent Menard is the Scientific Co-founder and Director of Microfluidics Research at Genturi Inc. He has a diverse background in the chemical sciences and has conducted research throughout his career with an underlying theme of innovation through nanotechnology. As a senior research scientist in the laboratory of Prof. J. Michael Ramsey at the University of North Carolina at Chapel Hill, he led a team of chemists and engineers developing nanofluidic platforms for high-throughput, high-resolution mapping of human genomes.

He is an expert in microfabrication and nanofabrication techniques, electron microscopy, surface chemistry, micro- and nanofluidics, and the characterization of biological macromolecules such as DNA using nanofluidic systems. Dr. Menard received a PhD in Analytical Chemistry from the University of Illinois at Urbana-Champaign in 2007, where he was supported through a NDSEG fellowship. He is an author on more than 25 peer reviewed journal articles and conference proceedings, an inventor on six pending and granted patents.

Peter Honkanen

Chief Executive Officer and Director

 

Peter Honkanen is the CEO and Director of Genturi Inc. He has served in leadership positions in the high tech and life science industries for the past 25 years. Prior to joining Genturi, Mr. Honkanen was the founding CEO of Aushon Biosystems, an ultra-sensitive, multiplexed immunoassay company acquired by Quanterix in January 2018. He also led the development and commercialization of numerous life science technologies at Affymetrix, Genetic Microsystems and General Scanning. He holds numerous patents covering the fabrication, processing and analysis of both genomic and proteomic assays.

Mr. Honkanen has an MS in Business Management from the Massachusetts Institute of Technology (MIT) Sloan School of Management and a BS in Electrical Engineering from Boston University. He is a former US Navy officer (Intelligence). He currently serves on the MIT Sloan Americas Executive Board.

Michael Dial, PhD

Director
Principal, Hatteras Venture Partners

 

Prior to joining Hatteras, Mike was a Vice President in Silicon Valley Bank’s Corporate Finance Scientific Founder and Director Scientific Co-founder and Group where he focused on emerging life science companies and venture capital funds. Prior Read Bio Director of Microfluidics Research to SVB, he held research scientist positions in the Department of Biochemistry at UNC-Chapel Hill, the Laboratory of Structural Biology at the National Institute of Environmental Health Sciences, and the UNC-Duke Michael Hooker Proteomics Center. He has performed research in the fields of cell cycle regulation, proteomics, and cancer therapy and holds a Ph.D. in Biochemistry and Biophysics from the University of North Carolina at Chapel Hill.

 

Mike is also the Manager of the Carolina Research Ventures Fund, a fund dedicated to UNC-Chapel Hill related start-ups. Mike serves on the boards of Genturi and Stride Therapeutics and is a board observer at Spyryx, Curoverse, and Lysosomal Therapeutics.

Keith L. Crandell

Director
Managing Director and Co-Founder, ARCH Venture Partners

 

Keith Crandell is a Managing Director and Co-Founder of ARCH Venture Partners, L.P., a global seed and early stage venture capital firm focused on innovations in the life and physical sciences. ARCH Venture partners is investing its ninth fund and manages $2.7 billion. Keith holds an M.B.A. from The University of Chicago (Booth), an M.S. in Chemistry from the University of Texas at Arlington, and a B.S. in Chemistry and Mathematics from St. Lawrence University.

Michael Albin, PhD

Director

 

Following a Ph.D. in chemistry at Pennsylvania State University and postdoctoral research in biochemistry at the California Institute of Technology, Michael worked at SYVA diagnostics followed by fifteen years at Applied Biosystems Inc rising to the role of VP of Science and Technology, and then VP of Strategic Technologies of the parent company Applera Corp, an S&P 500 company.

As VP of Science and Technology at Applied Biosystems Inc (now Life Technologies Inc.), Michael was responsible for R&D programs with a budget in excess of US$100 million and overseeing the development of the company’s product pipeline via internal development, investment and acquisition.

In recent years, Michael has worked as a private consultant focusing on technical and strategic assessments and the positioning of a wide range of companies in the life sciences, molecular diagnostics, and personalized medicine. In addition, he has been appointed to carry out due diligence for venture capital and other investment organizations worldwide.